21:27 GMT30 November 2020
Listen Live
    Get short URL

    MOSCOW (Sputnik) - The research team of Credit Suisse, one of Switzerland’s leading banks, has commended the frank discussion that the developers of the Russian Sputnik V vaccine recently had on its efficacy.

    "We were encouraged by the frank discussion of the human viral vector technology used and we view the 92 percent efficacy as a positive incremental readacross for the AstraZeneca data expected soon (possibly early December). However we would note that AZN uses a chimp adenovirus vector vs Sputnik that uses two different human adenovirus vectors", Credit Suisse said in a press release titled "Increasingly positive on Sputnik V COVID-19 vaccine" after observing the call between the Russian Gamaleya Institute and RDIF.

    The bank’s research team has noted that the participants in the call addressed the concerns about Russia’s speedy development of the vaccine.

    "The discussant pointed to Russia regulation allowing for early approval of drugs during epidemics if based on previously efficient platforms and if they have been through P2 trials", the press release read.

    Earlier in the week, the Russian Direct Investment Fund (RDIF) announced that Sputnik V vaccine had demonstrated 92 percent efficacy based on the first interim analysis, obtained 21 days after volunteers received the first injection.

    Sputnik V, which has been developed by the Gamaleya centre and produced in cooperation with the RDIF, became the world's first registered vaccine against COVID-19 when it was registered by the Russian Ministry of Health on 11 August. Many foreign countries have already ordered Sputnik V from Russia or expressed interest in purchasing the vaccine.

    coronavirus, COVID-19, vaccine, Switzerland, Credit Suisse Group AG, Russia
    Community standardsDiscussion